Xceleron's technologies speed drug development and reduce attrition rates by using the best model for human drug development - the human being.
Xceleron is recognised as THE world leader in Human Microdosing.
Xceleron's approach unlocks the potential of drug pipelines in exploratory clinical development through the application of ground breaking ultra-sensitive analytical techniques to enable:
At PHASE I (pharmacologic dose);
- META-ID™ The Solution to the US FDA's Guidance 'Safety Testing of Drug Metabolites'
- Human IV PK/Absolute Bioavailability Studies enables simultaneous oral / IV administration - the best, fastest and most cost-effective way of getting absolute bioavailability and clearance information
- Large Molecule Analysis How to distinguish 'artificial' endogenous materials from those naturally present in the body
At PHASE ZERO (sub-pharmacologic dose);
- Phase Zero/Human Microdosing get human ADME/PK data earlier than ever before with a sub-pharmacological non-GMP Microdose
Realise the potential of your pipeline - click on the links to gain fast access to these key applications.